Weekly subcutaneous gefurulimab delivered early is linked to lasting symptom improvement in patients with generalized ...
Pooled efficacy favored ravulizumab, improving QMG (MD –2.91) and MG-ADL (MD –2.64) after ~25 weeks, despite substantial between-study heterogeneity. Clinically meaningful MG-ADL response (≥2-point ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results